Available from stock

Thapsigargin

SKU: T0284

Category: Lipids, Fatty Acids

67526-95-8
CAS-Number: C₃₄H₅₀O₁₂
Molecular Formula: 650.75
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White crystalline powder
Identity: 1H-NMR

Properties

Solvents: Soluble in methanol, ethanol or DMSO.

Shipping: AMBIENT
Short Term Storage: -20°C
Long Term Storage: -20°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at -20°C.

Hazard statements: H315 - H319 - H334 - H335
Precautionary statements: P261 - P264 - P271 - P302 + P352 - P304 + P340 + P312 - P305 + P351 + P338
GHS Symbol: GHS07+GHS08
Signal word: Danger
Transportation: Not dangerous goods

Description: Thapsigargin is a non-competitive, cell permeable inhibitor of calcium transport by SERCAs (IC50 values are cell type-dependent and range from ~2-80 nM). Inhibition of SERCAs leads to an increase in intracellular calcium, which has been linked to cell activation, release of histamine from mast cells, and increased proliferation of certain types of cancer cells. Thapsigargin shows anti-inflammatory and anti-cancer effects.
Smiles: O=C1OC2C3=C(C)[C@@H](OC(/C(C)=C\C)=O)[C@@H](OC(CCCCCCC)=O)[C@]3([H])[C@](C)(OC(C)=O)C[C@@H](OC(CCC)=O)[C@]2(O)[C@@]1(O)C
InChi Key: IXFPJGBNCFXKPI-IVRBKYRWSA-N
References: (1) S.A. Patkar, et al.; Agents Actions 9, 53 (1979) , (2) H. Hakii, et al., J. Cancer. Res. Clin. Oncol. 111, 177 (1986) , (3) Y. Sagara, & G. Inesi; J. Biol. Chem. 266, 13503 (1991) , (4) A. Tsukamoto & Y. Kaneko; Cell Biol. Int. 17, 969 (1993) , (5) J.P. Beaver & P. Waring; Cell Death Differ. 3, 415 (1996) , (6) M. Treiman, et al.; Trends Pharmacol. Sci. 19,131 (1998) , (7) B. Tombal, et al.; Prostate 43, 303 (2000) , (8) S.B. Christensen, et al.; Anticancer Agents Med. Chem. 9, 276 (2009) , (9) N.T. Quynh Doan & S.B. Christensen; Curr. Pharm. Des. 21, 5501 (2015) (Review) , (10) N.T. Doan, et al.; Steroids 97, 2 (2015) (Review) , (11) A. Jaskulska, et al.; Int. J. Mol. Sci. 22, 4 (2020) (Review)
InChi: (1) N.A. Kuznetsova et al.: Russ. J. Gen. Chem. 71, 36 (2001)

Thapsigargin is a non-competitive, cell permeable inhibitor of calcium transport by SERCAs (IC50 values are cell type-dependent and range from ~2-80 nM). Inhibition of SERCAs leads to an increase in intracellular calcium, which has been linked to cell activation, release of histamine from mast cells, and increased proliferation of certain types of cancer cells. Thapsigargin shows anti-inflammatory and anti-cancer effects.

Artikelnummer: T0284 Kategorie: Lipids, Fatty Acids

Zusätzliche Informationen

Zusätzliche Informationen

Purity	≥98% (HPLC)
Appearance	White crystalline powder
CAS-Number	67526-95-8
Molecular Formula	C34H50O12
Molecular Weight	650.75
Identity	1H-NMR
Solvents	Soluble in methanol, ethanol or DMSO.
Smiles	O=C1OC2C3=C(C)[C@@H](OC(/C(C)=C\C)=O)[C@@H](OC(CCCCCCC)=O)[C@]3([H])[C@](C)(OC(C)=O)C[C@@H](OC(CCC)=O)[C@]2(O)[C@@]1(O)C
InChi Key	IXFPJGBNCFXKPI-IVRBKYRWSA-N
Shipping	AMBIENT
Short Term Storage	-20°C
Long Term Storage	-20°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at -20°C.
Hazard statements	H315 – H319 – H334 – H335
Precautionary statements	P261 – P264 – P271 – P302 + P352 – P304 + P340 + P312 – P305 + P351 + P338
GHS Symbol	GHS07+GHS08
Signal word	Danger
Transportation	Not dangerous goods
References	(1) S.A. Patkar, et al.; Agents Actions 9, 53 (1979), (2) H. Hakii, et al., J. Cancer. Res. Clin. Oncol. 111, 177 (1986), (3) Y. Sagara, & G. Inesi; J. Biol. Chem. 266, 13503 (1991), (4) A. Tsukamoto & Y. Kaneko; Cell Biol. Int. 17, 969 (1993), (5) J.P. Beaver & P. Waring; Cell Death Differ. 3, 415 (1996), (6) M. Treiman, et al.; Trends Pharmacol. Sci. 19,131 (1998), (7) B. Tombal, et al.; Prostate 43, 303 (2000), (8) S.B. Christensen, et al.; Anticancer Agents Med. Chem. 9, 276 (2009), (9) N.T. Quynh Doan & S.B. Christensen; Curr. Pharm. Des. 21, 5501 (2015) (Review), (10) N.T. Doan, et al.; Steroids 97, 2 (2015) (Review), (11) A. Jaskulska, et al.; Int. J. Mol. Sci. 22, 4 (2020) (Review)
InChi	(1) N.A. Kuznetsova et al.: Russ. J. Gen. Chem. 71, 36 (2001)
Quantity	1 mg, 5 mg, Bulk